Endocrinology

Patients with hypercortisolism and difficult-to-control type 2 diabetes who received mifepristone exhibited a significant HbA1c improvement in the Phase 4 trial.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

In this episode, hosts discuss the collaboration between Dexcom and Oura Ring, expanded compatibility of Omnipod 5 with Freestyle Libre 2, and Simplera CGM integration with the InPen.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

In this episode, hosts explore the most recent updates surrounding GLP-1 receptor agonists, including GLP-1 shortages and long-term data on tirzepatide.

In this episode, hosts discuss the latest developments in GLP-1 receptor agonists, with a particular focus on semaglutide.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

SF-36v2 scores also improved by 12 points with semaglutide compared with 6.5 points with placebo.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

The FDA's decision to issue a CRL was announced on October 08, 2024 and cites issues with the timing of the facility inspection.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

Ascendis Pharma has submitted a sBLA to the FDA for TransCon hGH for the treatment of adults with growth hormone deficiency.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A new study found glucagon-like peptide 1 receptor agonist use was associated with a lower risk of cirrhosis complications for patients with MASLD who did not have cirrhosis.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

Semaglutide lowers rates of cardiovascular and COVID-19-related deaths in patients with overweight/obesity, offering promising cardio-metabolic and non-cardiovascular benefits.

Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

FDA expands Omnipod 5 AID system for type 2 diabetes, marking the first AID system approved for both type 1 and type 2 diabetes management.

Dexcom's Stelo, the first OTC glucose sensor, launches in the US on August 26, 2024, offering 15-day wear and HSA/FSA eligibility for as low as $89.99 per 2-pack.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.